Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667823 · ClinicalTrials.gov registry record · Phase 3
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
A Phase 3 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 3
- Development phase
- 550
- Enrollment target
NCT00667823 is a Phase 3 study that has completed, run by Actelion. The registered enrollment target is 550 participants.
The verdict
NCT00667823, a Phase 3 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 550 participants
- Enrollment target
Study Summary
The main objective of the AC 055 303/SERAPHIN OL study, which will follow the AC 055 302/SERAPHIN study, will be to assess the long-term safety and tolerability of ACT 064992 in patients with symptomatic PAH.
Interventions
- DRUG Macitentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2008-10-17 |
| Est. Completion | 2020-12-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00667823
The ClinicalTrials.gov registry entry for NCT00667823 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Macitentan is the first listed.
NCT00667823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00667823 about?
NCT00667823 is a clinical study titled "Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension". The main objective of the AC 055 303/SERAPHIN OL study, which will follow the AC 055 302/SERAPHIN study, will be to assess the long-term safety and tolerability of ACT 064992 in patients with symptomatic PAH.
What is the current status of trial NCT00667823?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 550 participants. The study started on 2008-10-17. Estimated completion is 2020-12-07.
What interventions are being tested in trial NCT00667823?
The interventions under investigation include: Macitentan (DRUG).
Who is sponsoring clinical trial NCT00667823?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.